InspireMD Reports Q3 2026 Revenue of $2.24 Million, Exceeding Estimates
InspireMD (NSPR) reported third-quarter 2026 financial results, posting a GAAP earnings per share (EPS) loss of $0.12. While revenue declined 11% year-over-year to $2.24 million, the figure surpassed analyst expectations by approximately $0.24 million. The company's liquidity position saw a significant decrease, with cash and marketable securities totaling $19.25 million as of September 30, 2026, down from $54.21 million at the end of 2025. Despite the revenue dip, management is focusing on regulatory milestones, specifically an upcoming FDA submission intended to expand the market for its TCAR technology.
Tickers: $NSPR
Topics: cash flow earnings report GAAP EPS revenue